Literature DB >> 22543627

Familial Mediterranean fever: risk factors, causes of death, and prognosis in the colchicine era.

Servet Akar1, Feride Yuksel, Mehmet Tunca, Ozgul Soysal, Dilek Solmaz, Vedat Gerdan, Ali Celik, Gercek Sen, Fatos Onen, Nurullah Akkoc.   

Abstract

We assessed the risk factors and causes of death in patients with familial Mediterranean fever (FMF) in an era when colchicine is the standard therapy for all patients.This study included all FMF patients who had presented to any of the internal medicine, rheumatology, or nephrology clinics at Dokuz Eylul University Hospital between 1992 and 2009. Of the 650 patients with FMF identified, 587 (90.3%) had either a face-to-face (n = 380) or telephone (n = 193) interview, or were confirmed as deceased. A structured questionnaire was used to obtain socioeconomic and demographic data, presenting and cumulative clinical features, and disease severity scores.During the follow-up period mortality was analyzed by calculating age- and sex-standardized mortality ratio (SMR) according to the mortality statistics of the Turkish population. Factors predictive of mortality were evaluated using Kaplan-Meier and Cox proportional hazard models. Sixty-three (9.7%) patients whose initial demographic and major clinical characteristics were similar to the rest of the group could not be contacted during the study period.Most (94.2%) patients were on colchicine at the time of the study. Thirty-seven (6.3%) patients had biopsy-verified amyloidosis, and 44 (7.5%) had renal disease. During a median follow-up of 6 years, 14 patients (9 women) died, and amyloidosis and its related complications were the leading causes of death in 7 patients. Univariate analysis revealed that increasing age, coronary heart disease, hypertension, renal disease, and amyloidosis were associated with mortality. However, Cox regression analysis showed amyloidosis as the only significant predictor of mortality (p < 0.001). The overall patient survival rate was not significantly different from the age- and sex-matched Turkish general population (SMR, 1.48; 95% confidence interval, 0.817-2.49).Our findings suggest that although the survival of FMF patients in the colchicine era is comparable to that of the general population, renal involvement still predicts mortality.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22543627     DOI: 10.1097/MD.0b013e3182561a45

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  10 in total

1.  Autoinflammation: When is familial Mediterranean fever 'severe'?

Authors:  Helen J Lachmann; Paul A Brogan
Journal:  Nat Rev Rheumatol       Date:  2016-04-25       Impact factor: 20.543

2.  Phagocyte depletion inhibits AA amyloid accumulation in AEF-induced huIL-6 transgenic mice.

Authors:  Stephen J Kennel; Sally Macy; Craig Wooliver; Ying Huang; Tina Richey; Eric Heidel; Jonathan S Wall
Journal:  Amyloid       Date:  2014-01-22       Impact factor: 7.141

Review 3.  What is the best acute phase reactant for familial Mediterranean fever follow-up and its role in the prediction of complications? A systematic review.

Authors:  Burak Erer; Erkan Demirkaya; Seza Ozen; Tilmann Kallinich
Journal:  Rheumatol Int       Date:  2015-12-28       Impact factor: 2.631

4.  Mortality risk factors associated with familial Mediterranean fever among a cohort of 1.25 million adolescents.

Authors:  Gilad Twig; Avi Livneh; Asaf Vivante; Arnon Afek; Ari Shamiss; Estela Derazne; Dorit Tzur; Ilan Ben-Zvi; Amir Tirosh; Micha Barchana; Tamy Shohat; Eliezer Golan; Howard Amital
Journal:  Ann Rheum Dis       Date:  2013-03-16       Impact factor: 19.103

Review 5.  Cardiac disease in familial Mediterranean fever.

Authors:  Eren Erken; Ertugrul Erken
Journal:  Rheumatol Int       Date:  2017-10-20       Impact factor: 2.631

6.  Behcet's Disease With Cerebral Artery Infarction Caused by Cerebral Arteritis as an Early Symptom Only With Elevated Interleukin-8.

Authors:  Hao Yin; Yun Song; Meimei Zheng; Ju Han; Jiyou Tang
Journal:  Front Neurol       Date:  2019-10-22       Impact factor: 4.003

7.  High prevalence of spondyloarthritis and ankylosing spondylitis among familial Mediterranean fever patients and their first-degree relatives: further evidence for the connection.

Authors:  Servet Akar; Ozgul Soysal; Ali Balci; Dilek Solmaz; Vedat Gerdan; Fatos Onen; Mehmet Tunca; Nurullah Akkoc
Journal:  Arthritis Res Ther       Date:  2013-01-28       Impact factor: 5.156

Review 8.  The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases.

Authors:  Silvia Federici; Alberto Martini; Marco Gattorno
Journal:  Front Immunol       Date:  2013-10-31       Impact factor: 7.561

9.  P wave dispersion and QT dispersion in adult Turkish migrants with familial mediterranean fever living in Germany.

Authors:  Arnd Giese; Ahmet Ornek; Mustafa Kurucay; Kaffer Kara; Helmut Wittkowski; Faekah Gohar; Bjoern A Menge; Wolfgang E Schmidt; Christoph Zeidler
Journal:  Int J Med Sci       Date:  2014-08-21       Impact factor: 3.738

10.  Cardiovascular disease risk assessment in patients with familial Mediterranean fever related renal amyloidosis.

Authors:  Micol Romano; David Piskin; Roberta A Berard; Bradley C Jackson; Cengizhan Acikel; Juan J Carrero; Helen J Lachmann; Mahmut I Yilmaz; Erkan Demirkaya
Journal:  Sci Rep       Date:  2020-10-27       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.